 Shares of BAVA, 10.04 jumped 11 as the drugmaker said it signed a contract amendment with Public Health Canada thats valued at up to 434 million over ten years. Under the new contract amendment, the majority of the confirmed order for Imvamune will be delivered in 2023, Bavarian Nordic said. 